(S)-N-(2-Benzoyl-4-Chlorophenyl)-1-(3,4-Dichlorobenzyl)Pyrrolidine-2-Carboxamide Hydrochloride

In the manufacture of direct oral anticoagulants targeting factor Xa, this pyrrolidine-2-carboxamide derivative serves as a chiral P4 building block whose (S)-configuration at C2 is preserved throughout a sequence of amide couplings and salt metatheses. Acceptance into a cGMP synthesis chain is contingent upon the demonstration of an enantiomeric excess not less than 99.0% as determined by chiral HPLC using a polysaccharide-based column per USP 〈621〉, with a single unknown impurity ceiling of 0.10% area normalisation. The hydrochloride salt is routinely pre-dried in a vacuum tray oven at 40 °C and ≤10 mbar until Karl Fischer titrimetry reads ≤0.2% w/w water, a specification driven by the sensitivity of the subsequent HATU/DIPEA-mediated coupling to residual moisture. In a validated generic protocol executed in a 100 L glass-lined reactor equipped with a retreat-curve impeller, the substrate is dissolved in anhydrous N,N-dimethylformamide (8 L kg⁻¹ substrate) and treated with 1.08 eq of 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) and 2.2 eq of N,N-diisopropylethylamine at −15 °C to suppress diketopiperazine formation; the acid component—typically a Boc-protected D-phenylalanine analogue—is added as a pre-activated mixed anhydride over 45 min, after which the batch is held at 0 ± 2 °C for 16 h. Quenching with 5% w/v citric acid induces phase separation, and the dichloromethane extract is washed with 7% NaHCO₃ to remove residual HATU by-products whose carryover poisons downstream hydrogenolysis catalysts. Batch records from three consecutive production campaigns at pilot scale indicate that crystallisation from isopropanol/water (4:1 v/v) with controlled cooling at 0.2 °C min⁻¹ reproducibly delivers a non-hygroscopic crystalline polymorph (Form A) with a melting endotherm onset of 198–201 °C by differential scanning calorimetry. Terminal API syntheses that utilise this intermediate—such as those yielding betrixaban and edoxaban analogues—must demonstrate removal of the 3,4-dichlorobenzyl-derived genotoxic impurity to below the threshold of toxicological concern (1.5 µg day⁻¹) per ICH M7(R2), achieved through a combination of activated carbon treatment and multiple reslurry cycles monitored by LC-MS/MS with an LOQ of 0.1 ppm.

How Are DPP-4 Inhibitor Intermediates Validated Against ICH Q3D Elemental Impurity Limits?

When the pyrrolidine scaffold is incorporated as a proline-mimetic into the design of dipeptidyl peptidase-4 inhibitors—a structural motif found in the backbones of gemigliptin and anagliptin—the residual palladium burden originating from a Suzuki-Miyaura cross-coupling step used to install the benzoyl-chlorophenyl fragment becomes the primary regulatory checkpoint. Process development reports filed under EMA/CHMP/ICH/353369/2013 establish that palladium content in the isolated hydrochloride must not exceed 10 ppm for an oral solid dosage form with a maximum daily intake of 100 mg, a limit routinely verified by inductively coupled plasma mass spectrometry after microwave digestion. The cross-coupling itself is performed with 0.5 mol% Pd(PPh₃)₄ in a deoxygenated toluene/ethanol/water (5:2:1) ternary system at 70 °C, but post-reaction scavenging with trimercaptotriazine-functionalised silica gel (250 g kg⁻¹ crude) is what reduces Pd to single-digit ppm values; failure to maintain the scavenger contact time above 6 h leads to values exceeding 25 ppm and triggers reprocessing. Once the free base is liberated with 1 M NaOH and the hydrochloride reformed by treatment with 1.2 eq of HCl in ethyl acetate, the dried product is subjected to residual solvent analysis by headspace GC-FID per USP 〈467〉 procedure A, with Class 2 tolerances of 290 ppm for toluene and 1870 ppm for ethanol applied. In the final coupling to a β-amino acid warhead—generally conducted at −5 °C under Schotten-Baumann conditions—the hydrochloride is neutralised in situ and acylation completion is tracked by in-line ReactIR monitoring of the acid chloride peak at 1795 cm⁻¹; deviation beyond ±3% from the target 1.0 eq of acid chloride leads to a pronounced increase in the dimeric by-product (observed at m/z 785.2), which co-elutes with the target peptidomimetic during reversed-phase purification.

Process Robustness of Single-Isomer Stability During Canonical Peptide Coupling

Retention of the (S)-stereochemistry at the pyrrolidine α-carbon becomes acutely challenging when this chiral amide enters a carbodiimide-driven coupling loop in the construction of HCV NS3/4A serine protease inhibitors of the macrocyclic class, where the 3,4-dichlorobenzyl group imposes significant steric demand and slows the rate of acylation relative to epimerisation. Under standard EDC·HCl (1.15 eq)/HOBt·H₂O (1.20 eq) activation in DMF at 0 °C, the formation of the oxazolone intermediate is mitigated by the addition of 0.3 eq of copper(II) chloride dihydrate, a racemisation-suppressing Lewis acid first described in fragment couplings of this type. The epimer content is quantified by a dedicated normal-phase HPLC method employing a Chiralpak AD‑H column (250 × 4.6 mm) with a mobile phase of n-hexane/ethanol/diethylamine (80:20:0.1) and UV detection at 254 nm; the (R)-isomer elutes at a relative retention time of 1.38 and must not exceed 0.8% area for the batch to progress to the ring-closing metathesis step. Thermal stress studies conducted on the isolated intermediate show a 0.15% per hour drift in epimer content at 25 °C in solution, mandating that all coupling work-up steps are completed within 8 h of neutralisation. The final drug substance derived from this sequence—a potent pan-genotypic protease inhibitor requiring a 50 mg daily dose—relies on the integrity of this chiral handle for its P2-P4 binding cleft fit; crystallographic data (PDB entry reference accessible via supplementary materials) confirm that a 2° deviation in the dihedral angle of the pyrrolidine ring reduces inhibition constants by approximately 1.5 log units.

When the 3,4-Dichlorobenzyl Substituent Dominates Opioid Receptor Binding Kinetics

Investigations into κ-opioid receptor (KOR) antagonists for the management of pruritus and visceral pain have exploited this carboxamide as a rigidified probe molecule wherein the 3,4-dichlorobenzyl group engages a hydrophobic sub-pocket adjacent to transmembrane helix 3. Synthesis of a focused chemical library using the hydrochloride as a universal intermediate requires a divergent amidation protocol conducted on a Chemspeed SWAVE automated platform under strictly inert conditions (glovebox with O₂  < 50 ppm, H₂O  < 20 ppm) to prevent deactivation of the lithiated intermediates. A typical run dispenses 0.1 mmol of the deprotonated amide—generated by treatment with 1.05 eq of lithium bis(trimethylsilyl)amide in THF at −78 °C—and couples it with a series of N-Fmoc-α-amino aldehydes to yield secondary alcohol diastereomers that are later oxidised to the ketone. Conversion rates monitored by UPLC-PDA at 220 nm exceed 85% within 30 min for all reactive aldehydes, but sterically hindered derivatives carrying an ortho-substituted benzyl group require a doubling of the aldehyde stoichiometry to 2.5 eq to drive conversion above 60%. Biological evaluation of the resulting compounds against the human KOR (HEK293 membrane preparations, [³H]U69,593 displacement) reveals that shifting the chlorine substitution pattern on the benzyl moiety from 3,4-dichloro to 2,4-dichloro raises the K_i from 0.9 nM to 18 nM, confirming the regiospecificity demanded of this building block.

Continuous Flow Alkylation of the Pyrrolidine Nitrogen for CGRP Antagonist Backbones

The reliance of calcitonin gene-related peptide (CGRP) receptor antagonists on a central pyrrolidine‑2‑carboxamide core positions this chlorinated hydrochloride as a late-stage diversifiable intermediate, particularly in the synthesis pathway of ubrogepant progenitors where N‑alkylation with 3,4‑dichlorobenzyl bromide constitutes the final residual step before salt resolution. In a Corning Advanced-Flow G1 SiC reactor, a 0.25 M solution of the free base in acetonitrile is combined with 1.15 eq of the benzyl bromide and 1.5 eq of finely ground potassium carbonate within a residence time module calibrated to 180 s at 60 °C and 3 bar back-pressure, delivering a steady-state conversion of 97.3 ± 0.4% over 8 h of uninterrupted operation. In-process control utilises an online PATROL UPLC system that samples the reactor effluent every 15 min and integrates the N‑benzylated product peak against a calibrated response factor; any drift below 95% triggers an automated diversion valve. The crude hydrobromide by-product is converted to the hydrochloride by a sequential ion-exchange approach employing Amberlyst A‑21 resin, with chloride breakthrough confirmed by silver nitrate titration, after which polymorphic Form B is crystallised from methyl isobutyl ketone/heptane (1:3) to furnish a product with a particle size D₉₀ of 55 µm, suited for the subsequent dry-media milling step required for micronisation of the final antagonist. The entire continuous campaign operates under ISO 14644‑1 Class 8 controlled atmosphere, and cleaning validation between batches is performed using swab recoveries with an acceptance criterion of ≤10 ppm of the active intermediate on product-contact surfaces.

*No Pd used in this synthesis variant; a strict limit of ≤20 ppm nickel (ICP-MS) applies if Raney nickel is employed for debenzylation.

Granular compliance data with companion pharmacopoeial monographs and ICH guidelines is tabulated below. Declarations of conformity are issued only after successful registration stability studies conducted under ICH Q1A(R2) long-term conditions (25 °C/60% RH) and intermediate conditions (30 °C/65% RH) across a minimum of 12 months for each of the three primary application pathways described. The heavy-metal suite assessment follows ICH Q3D Option 1 with a permitted daily exposure for parenteral administration of ≤2.5 µg day⁻¹ for cadmium, ≤5 µg day⁻¹ for lead, and ≤60 µg day⁻¹ for palladium when injectable formulations are contemplated.